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S U M M A R Y
Objectives: This study aims to elucidate the role of breastfeeding on vertical transmission of HCMV and
HBV and to investigate the difference in perinatal transmission via breast milk between HBV and HCMV.
Methods: This detailed study monitored the kinetics of viral DNA load in maternal milk for both HBV and
HCMV, demonstrated the rate of transmission to infants, and compared HBV infection rate with that of
HCMV.
Results: There was no difference in overall DNAlactia+ between HBV (23.86%) and HCMV (29.54%,
P=0.140) for seropositive mothers, while HBsAg prevalence (0.75%) was signiﬁcantly lower than HCMV
IgG+ (27.44%, P<0.001) for the breast-fed babies. Between breast-fed babies of seropositive mothers and
those of seronegative mothers, HBV infection rate had no difference (HBsAg+: 0.75% vs 0%, P=0.538;
DNAemia+: 0.38% vs 0%, P=0.664), but HCMV infection rate of the former was signiﬁcantly higher than
that of the latter (IgG+: 27.07% vs 18.00%, P=0.045; DNAemia+: 15.79% vs 4.00%, P=0.027).
Conclusions: Breastfeeding is not a risk factor for maternal-to-infant transmission of HBV after the
recommended prophylaxis is implemented. However, viral DNA positive breast milk is a main source for
vertical transmission of HCMV to infants who are not protected by a standard immunoprophylaxis
protocol.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Hepatitis B virus (HBV) infection is a major global health
problem and remains a leading cause of acute and chronic hepatitis
B, liver cirrhosis and hepatocellular carcinoma.1 Mother-to-child
transmission of HBV is among the most important causes of
chronic HBV infection and is the commonest mode of transmission
worldwide.2 A baby infected with HBV perinatally has a 90%
chance of developing chronic HBV infection (compared to less than
10% of people infected as adults develop chronic HBV infections).3,4
Human cytomegalovirus (HCMV), a betaherpesvirus, represents
the major infectious cause of birth defects and is found in both the
developed industrial societies and in isolated aboriginal groups.5
About 10-25% of infants are infected by the age of 6 months
following transmission from their mothers via the placenta, during
delivery, or by breastfeeding.6 Approximate 10% of congenitally* Corresponding author. Tel.: +86 371 63974618; fax: +86 371 63934118.
E-mail address: yanxiahe1961@126.com (Y. He).
http://dx.doi.org/10.1016/j.ijid.2015.06.002
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).infected infants will develop neurological impairments, perma-
nent hearing loss or vision loss.7
The presence of HCMV and HBV particles and DNA in breast
milk has been conﬁrmed for decades.8 However, studies present a
discrepancy between HBV vertical transmission via breast milk
and that of HCMV.9–13 On the one hand, breast-feeding has a major
impact on cytomegaloviral infections in early life.11–13 HCMV can
be reactivated in latently infected mothers and is shed within the
breast milk.11 High viral DNA in maternal milk is correlated with
perinatal transmission.12 On the other hand, even though the HBV
antigen has been detected in breast milk, there is no evidence that
breast-feeding increases the risk of mother-to-child transmis-
sion.9,10 The World Health Organization postulates that chronic
HBV infection of the mother could not be an argument against
breastfeeding.8,9 However, some researchers and clinicians disap-
prove it based on the results of some studies that have investigated
the content of viral markers in human milk.9,13
To conﬁrm or dispute the discrepancy and to reveal the
reason(s) why the difference, if any, exists between HBV
transmission to infants via maternal milk and that of HCMV, thisciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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and HCMV infection rates for breast-fed babies born to seropositive
mothers with both HBV and HCMV. This was a detail study to
elucidate the kinetics of viral DNA positivity in maternal milk for
both HBV and HCMV and to demonstrate the timely rate of
transmission to infants. And the background of maternal and
newborn HCMV/HBV prevalence in central China was also
investigated for better understanding of the present situation of
mother-to-child HBV and HCMV transmission.
2. Patients and Methods
2.1. Study design and population
The study population was comprised of 8150 mothers and their
neonates (total 8312, 613 preterm and 7699 term; 4332 boys and
3980 girls; 3328 vaginal delivery and 4984 caesarean section;
including 156 twins and 3 triplets) born at the Second Afﬁliated
Hospital of Zhengzhou University, Children’s Hospital of Zhengzhou
or Henan Provincial People’s Hospital during the period of January
2013 to December 2014. The three are referral hospitals for Henan
province, so patients visiting the hospitals come from all over the
area. The maternal age ranged from 17 to 43 years old
(mean=28.52y), while the age of the neonates was  5 days old
(mean=2.13d); birth weight was 705-5110 g (mean=3455 g);
gestational age at birth was 28-43 weeks (mean=38.5w). HCMV-
speciﬁc immunoglobulin (Ig) G and IgM tests were ordered routinely
for pregnant women and neonates as part of TORCH (Toxoplasma,
Rubella virus, Cytomegalovirus and Herpes simplex virus) surveil-
lance. If the IgM and/or IgG test was positive, detection of viral DNA
in PBMC (peripheral blood mononuclear cells) was performed. HBV
markers, including HBsAg (hepatitis B surface antigen) and
HBeAg(hepatitis B e antigen), were also ordered routinely as part
of HBV, HCV, HIV and TP surveillance. If HBsAg was positive,
detection of viral DNA in serum was performed. To evaluate the
effects of viral DNAlactia on vertical transmission, 380 lactating
mothers (300 seropositive and 80 seronegative) and their children
were enrolled. But 264 seropositive mothers (positive for both
HBsAg and HCMV IgG but asymptomatic infection), 50 seornegative
(for both HBsAg and HCMV IgG) mothers and their infants
(266 infants born to seropositive mothers, including 2 twins, and
50 born to seronegative mothers) went through the whole follow-up
duration of 6 months. These infants and their mothers provided
blood and/or breast milk for serological tests and viral DNA load
determination from day 1 to month 6 postpartum. Breast-fed meant
infants were fed fresh untreated breast milk from their own
mothers. Feeding was started as early as possible, normally between
24 and 48 h after birth.
2.2. Ethical approval
The study was approved by the ethics committee of The Second
Afﬁliated Hospital, Zhengzhou University, ethics committee of
Children’s Hospital of Zhengzhou, and ethical committee of Henan
Provincial People’s Hospital. Reviewing medical ﬁles was approved
by the ethical committee. Informed consent was obtained from all
patients or their legal guardians prior to enrolling in the study. All
experiments were performed in compliance with relevant laws
and guidelines.
2.3. Questionnaire
A questionnaire included demographic information of the
mother and her child/children, vaccination against hepatitis B,
especially timely ﬁrst dose vaccine and administration of HBIG
(hepatitis B immunoglobulin) in the child. Administration ofHBIG and the ﬁrst dose vaccine was further validated by the
hospital discharge records. The injection of second and third doses
vaccine was conﬁrmed by children’s vaccination records. Among
the 8312 neonates, 8310 received hepatitis B vaccine within 24 h of
birth or sometime later and 8304 were administrated completion
of the vaccine series. All 266 infants born to infected mothers in the
study received HBIG within 24 h of birth in addition to HBV
vaccine. HBV vaccine administered to infants was a 10 mg dose
from Beijing Tiantan Biological Products Company, Ltd., or Dalian
Hissen Bio-pharm Company, Ltd. HBIG was administered as a
single 100 IU dose from Hualan Biological Engineering Inc. In this
study, there were no women receiving antiviral treatment during
pregnancy. Additional clinical data were obtained from case ﬁles
and laboratory records.
2.4. Sample collection and processing
2-3 mL of peripheral blood from each patient was drawn and
separated by centrifugation at 4,000 rpm for 10 min. Sera were
tested for HBV markers, HBV-DNA, HCMV IgM and IgG immedi-
ately or frozen in aliquots at -20 8C until use.
EDTA-anticoagulated blood was obtained 1 mL from each for
isolation of peripheral blood mononuclear cells (PBMC). Prepara-
tion of PBMC was performed immediately after collection by
gradient centrifugation. PBMC were stored at -20 8C until HCMV
DNA preparation and PCR analysis.
Fresh expressed breast milk (1-2 mL for each) was collected in a
sterile tube and centrifuged at 1,500 rpm for 15 minutes. The
creamy fat globules layer was discarded to eliminate or reduce the
inhibitory effects of fat on DNA ampliﬁcation. The supernatant
milk whey was passaged through 0.2 mm-pore syringe ﬁlter to
eliminate cellular debris and centrifuged further at 12,000 rpm for
5 min. After pipetting off the supernatant the remaining sediment
was frozen until HBV and HCMV DNA extraction. The reason why
only whey was sampled was that separation procedures for milk
resulting in preparation of the cell and fat-free milk whey fraction
became a standard for sensitive viral DNA detection by PCR and
that milk cells do not play a predominant role in virus transmission
in many experiments.12
2.5. HBsAg, HBeAg, HCMV IgM/IgG antibody tests
HBsAg, HBsAb, HBeAg, HCMV-speciﬁc IgM and IgG antibodies
were determined for serum samples by electrochemiluminescence
immunoassay (ECLIA) using commercial kits of HBsAg II, Anti-HBs,
HBeAg, CMV IgM and CMV IgG (Roche Diagnostics GmbH,
Mannheim, Germany) on automatic cobas e601 (Roche Diagnostics
GmbH, Mannheim, Germany) analyzer according to the manu-
facturer’s instructions. Based on manufacturer’s recommenda-
tions, HBsAg, HBeAg, and HCMV IgM index values 1.0 COI (cutoff
index) were considered positive, while HBsAb values 10.0 IU/L
and HCMV IgG values 1.0 U/mL were considered positive,
respectively. The measuring range for HBsAb was 2.0-1000.0 IU/L
and IgG 0.25-500 U/mL, respectively.
2.6. DNA extraction, ampliﬁcation and detection
HBV and HCMV DNA was isolated, ampliﬁed and determined
from serum/PBMC and milk using Diagnostic Kit for Quantiﬁcation
of Hepatitis B Virus DNA and Diagnostic Kit for Quantiﬁcation of
Human Cytomegalovirus DNA (DAAN Gene, Guangdong, China).
The heat-extraction-method was used following the manufac-
turer’s speciﬁcations. Real-time ﬂuorescence quantitative PCR
(polymerase chain reaction) for HBV and HCMV DNA load
detection was performed on LightCycler 1.5 (Roche Diagnostics
GmbH, Mannheim, Germany) following the manufacturer’s
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Master mixes were based on a ready-to-use kit containing Taq-
DNA-polymerase, dNTP-mix and supplemented with the primer,
MgCl2, the ﬂuorescein-labeled hybridization probe and Tris-HCl
buffer. [HCMV-speciﬁc DNA primer and probe targeting the
conservative immediate-early (IE) 1 gene coding region was used
to amplify a 86-bp fragment and HBV-speciﬁc DNA primer and
probe targeting the S outer membrane protein coding region was
used to amplify a 89-bp fragment.] After pipetting 2 mL of the DNA
preparations, 18 mL of the master mixes was added into disposable
glass capillary cuvettes. The LightCycler experimental protocol
was: 2 min at 93 8C for pre-denaturation, followed by 40 cycles of
5 s denaturation at 93 8C, 45 s annealing and elongation at 57 8C.
The ramp rates were programed at 20 8C/s. Fluorescence was
measured at the end of each cycle. Standards and negative controls
were quantiﬁed along with test samples every ampliﬁcation run.
Positive samples were conﬁrmed by melting curve analysis and
results were then calculated as IU/mL for HBV or copies/mL for
HCMV based on comparisons to co-ampliﬁed standards. The limit
of detection of the quantitative assay was 100 IU/mL for HBV DNA
and 500 copies/mL for HCMV DNA.
2.7. Statistical analysis
Chi-square test or Fisher’s exact test was applied to determine
whether there was a signiﬁcant difference between the frequen-
cies using IBM SPSS Statistics for Mac, version 22.0 (International
Business Machines Corporation, Armonk NY, USA). Two-tailed
P-values of <0.05 were considered to be of statistical signiﬁcance.
3. Results
3.1. Prevalence of HBV and HCMV in the study population
There were 4.67% (381/8150) of mothers found HBsAg+,
including 94 (1.15%) of them positive for both HBeAg and HBsAg
during perinatal period. Meanwhile, the HCMV IgG+ rate was
74.91% and IgM+ was 1.13% for these mothers, among which there
were 171 (2.10%) with viral DNA detectable in PBMC. There were
signiﬁcantly more women infected with HCMV than those infected
with HBV (P<0.001). Interestingly, HBV DNA positivity in serum
was 19.16% (73/381) for HBsAg+ mothers, which was signiﬁcantly
higher compared to HCMV DNA positivity in PBMC for HCMV IgG+
mothers (2.80%, 171/6105, P<0.001). But the overall HBV
DNAemia+ (0.90%, 73/8150) for all the mothers was signiﬁcantly
lower than HCMV DNAemia+ (2.10%, 171/8150, P<0.001). As for
the newborns, HBV infection rate was only 0.02% (2/8312) and
none of them were found to be HBeAg+ or DNA+ in serum, while
the HCMV IgG+ was 56.10%, IgM+ was 1.22% and HCMV DNAemia+
was 5.52%, respectively. The HBV infection rate for babies was
signiﬁcantly lower than that of HCMV, irrespective of whether it
referred to sero-positivity (P<0.001) or DNAemia+ (P<0.001).
(Table 1)Table 1
Maternal and newborn infection status of HBV and HCMV
Study population
(n)
HBV infection n (%) 
HBsAg + HBeAg+ DNAe
Mothers (8150) 381 (4.67) 94 (1.15) 73 (0
Newborns (8312) 2(0.02) 0(0) 0(0)
P <0.001a <0.00
<0.00
a HBsAg+ compared to HCMV IgG+ for mothers; b. HBV DNAemia+ compared to HCMV 
381) compared to HCMV DNAemia+ for HCMV seropositive mothers (2.80%, 171/6105);
HCMV DNAemia+ for newborns3.2. Impact of breast-feeding on HBV and HCMV vertical transmission
In order to elucidate the role of breastfeeding on mother-to-
child transmission of HCMV and HBV infection, 264 lactating
mothers (seropositive for both HBV and HCMV but asymptomatic
infection) and their 266 infants (including 2 twins) were detected
for infection status of HBV and HCMV, with 50 breast-fed babies of
seronegative mothers for both HBV and HCMV as control.
3.2.1. The dynamics of viral DNAlactia+ in seropositive and
seronegative mothers
For seropositive mothers with both HBV and HCMV, there were
63 (23.86%) mothers who shed HBV DNA and 78 (29.54%) who shed
HCMV DNA into the milk during the 6 months after delivery. There
was no difference between the overall DNAlactia+ of HBV and that
of HCMV (P=0.140). In detail, HBV DNAlactia+ slightly increased
from 21.59% at day 1 to 23.48% at month 1 and then it dropped
from 20.45% at month 3 to 15.53% at month 6 postpartum.
Meanwhile, HCMV DNAlactia+ dramatically elevated from 5.68% at
beginning to 28.79% at month 1, and then it decreased from 21.21%
at month 3 to 12.50% at month 6. The DNAlactia+ of HBV was
signiﬁcantly higher than that of HCMV at day 1 postpartum
(P<0.001), thereafter, there was no difference between them
during the lactation of 6 months (P>0.05). In contrast, none of the
seronegative mothers had detectable HBV DNA in milk during
6 months postpartum. Interestingly, there were 2 of them (0.76%)
shed HCMV DNA into milk during this time. (Table 2).
3.2.2. Serological tests and viral DNA detection for breast-fed infants
of seropositive mothers
During 6 months after birth, the overall HBsAg positive rate was
only 0.75% (2/266) and HBV DNA positivity in serum was only 0.38
(1/266) for babies of seropositive mothers for both HBV and HCMV.
But protective HBsAb was produced in more and more babies from
1 (0.38%) to 126 (47.37%). Meanwhile, the overall HCMV IgG+ was
27.44% (73/266), which was signiﬁcantly higher than HBsAg+
(P<0.001). And DNA positivity of HCMV (15.79%) was also
signiﬁcantly higher than that of HBV (P<0.001). Furthermore,
HCMV infection rate increased gradually during 6 months
postpartum, irrespective of whether it referred to IgG+ (from
12.41% to 27.44%) or viral DNAemia+ (from 0.38% to 15.79%).
(Table 3).
3.2.3. Serological tests and viral DNA detection for breast-fed infants
of seronegative mothers
For 50 babies of seronegative mothers as the control group,
there were none infected with HBV during 6 months after birth, but
7 (14%) of them were HCMV IgG+ and 2 (4%) had detectable HCMV
DNA in PBMC. HCMV infection rate was signiﬁcantly higher than
that of HBV, according to seropositivity (P=0.002) or to viral
DNAemia+ (P=0.006, Table 4).
On the other hand, HBV infection rate showed no difference
between babies of seropositive mothers and the control group,HCMV infection n (%)
mia+ IgG+ IgM+ DNAemia+
.90) 6105(74.91) 92 (1.13) 171(2.10)
 4663(56.10) 101(1.22) 459(5.52)
1b <0.001d <0.001e
1c
DNAemia+ for mothers; c. HBV DNAemia+ for HBV seropositive mothers (19.16%, 73/
 d. HBsAg+ compared to HCMV IgG+ for newborns; e. HBV DNAemia+ compared to
Table 2
HBV and HCMV DNA positivity in maternal milk from seropositive and seronegative mothers
Milk collection time point postpartum Seropositive mothers n (%) Seronegative mothers n (%)
HBV HCMV Pa HBV HCMV
1d 57(21.59) 15(5.68) <0.001 0(0) 0(0)
1m 62(23.48) 76(28.79) =0.166 0(0) 2(0.76)
3m 54(20.45) 56(21.21) =0.830 0(0) 1(0.38)
6m 41(15.53) 33(12.50) =0.316 0(0) 0(0)
Overall 63(23.86) 78(29.54) =0.140 0(0) 2(0.76), P<0.001 b
a HBV DNAlactia+ compared to HCMV DNAlactia+ for seropositive mothers; b. HCMV DNAlactia+ for seropositive mothers compared to that of seronegative mothers
Table 3
HBV and HCMV sero-positivity and DNAemia+ in infants of seropositive mothers for both HBsAg and HCMV IgG
Specimen collection time point postpartum HBV n (%) HCMV n (%)
HBsAg+ HBsAb+ DNAemia+ IgG+ DNAemia+
1d 1(0.38) 1(0.38) 0(0) 33(12.41) 1(0.38)
1m 1(0.38) 57(21.43) 0(0) 41(15.41) 23(8.65)
3m 2(0.75) 98(36.84) 1(0.38) 54(20.30) 35(13.16)
6m 2(0.75) 126(47.37) 1(0.38) 73(27.44) 42(15.79)
P <0.001a - <0.001b - -
a HBsAg+ compared to HCMV IgG+; b. HBV DNAemia+ compared to HCMV DNAemia+.
Table 4
HBV and HCMV sero-positivity and DNAemia+ for infants of seronegative mothers for both HBsAg and HCMV IgG
Specimen collection time point postpartum HBV n (%) HCMV n (%)
HBsAg+ HBsAb+ DNAemia+ IgG+ DNAemia+
1d 0(0) 18(36.00) 0(0) 0(0) 0(0)
1m 0(0) 33(66.00) 0(0) 1(2.00) 0(0)
3m 0(0) 37(74.00) 0(0) 4(8.00) 1(2.00)
6m 0(0) 39(78.00) 0(0) 7(14.00) 2(4.00)
P 0.002a - 0.006b - -
a HBsAg+ compared to HCMV IgG+; b. HBV DNAemia+ compared to HCMV DNAemia+
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(0.38% vs 0%, P=0.664). However, HCMV infection rate of babies to
seropositive mothers was signiﬁcantly higher than that of the
control group, according to both IgG+ (27.44% vs 14.00%, P=0.045)
and DNAemia+ (15.79% vs 4.00%, P=0.027). (Figure 1)
4. Discussion
Maternal and newborn HBsAg prevalence in this study is 4.67%
and 0.02%, respectively, which is consistent with other internationalFigure 1. Serological tests and viral DNA detection of HBV and HCMV for infants of
seropositive and seronegative mothers.and national reports showing that HBsAg prevalence has greatly
diminished among populations aged 1-59 years, including children
age <5 years.1,2 Based on the national serosurvey in 2006, the
Chinese population’s prevalence of HBsAg has decreased to 7.2% for
all age groups, compared to 9.8% found in the 1992 serosurvey.2,4 The
decline of HBsAg prevalence can be attributed primarily to the
vaccination program of China, including the recommendation of
hepatitis B vaccine for routine immunization of infants in 1992,
requirement of all infant vaccinations given at no charge to parents
in 2005, and all infants given immunoprophylaxis at birth in 2010.1,4
The vaccination program in China has been regarded as a successful
story in preventing hepatitis B through universal infant vaccination.
Moreover, the HBV infection rates have no difference between HBV-
infected mothers’ breastfed children and non-infected mothers’
breast-fed children protected by currently recommended immu-
noprophylaxis against hepatitis B, indicating that breastfeeding in
high-risk children does not add any risk for vertical transmission of
HBV. In addition, breastfeeding may not interfere with humoral
immune response to hepatitis B vaccine and HBIG, as 47.37% of
breast-fed babies born to infected mothers are found to be HBsAb+ at
month 6 postpartum, which is in accordance with other ﬁndings.9,10
On the other hand, the HCMV-IgG seropositive rate presented
here is signiﬁcantly higher for both mothers and newborns. One of
the reasons for the high seroprevalence may be related to
socioeconomic conditions,14,15 since Zhengzhou is the capital city
of Henan which is an agricultural province with poor economic
conditions in central China. To some extent, the IgG+ proportion
can be generalized to the Chinese as an overall population, because
Henan is the most populous province in China. But the relatively
low level of DNAemia+ indicates fewer incidences of acute/primary
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infection occurs in some lactating mothers who shed viral DNA in
milk during 6 months after delivery. Fed with the viral DNA
positive milk, more infants are infected HCMV than those fed with
DNA negative milk, indicating that breast milk is a main source for
HCMV vertical transmission. Research into probable viral trans-
mission mechanisms via breastfeeding is still open.17
Interestingly, a contradiction emerges regarding whether breast
milk may pose additional risk for perinatal virus transmission. There
is no difference in maternal viral DNAlactia+ between HCMV and
HBV, nevertheless, more HCMV transmission to infants via
breastfeeding occurs than does HBV. The main reason may be the
impact of HBV vaccination for all babies and HBIG for infants born to
infected mothers. For the group reported in this study, which had
especially good adherence to a standard immunoprophylaxis
protocol, the HBV transmission rate is greatly reduced compared
to that before hepatitis B vaccine was recommended in 1992.1
Therefore, full adherence to the prophylaxis recommendations is a
more important point than whether the mother breastfeeds or not in
reducing the mother-to-child transmission.8,9 To replicate the
success of HBV prevention, vaccination may be the most effective
measure to control HCMV infection, and development of a vaccine
against HCMV has been identiﬁed as a high priority goal in
biomedical research.18,19 But no HCMV vaccine has been licensed till
now due to unsatisfactory results of a clinical trial on the current
vaccine candidates.20
However, there are still measures that should be taken to try to
decrease the risks associated with breast milk transmission of
HCMV. Public health disease prevention programs usually work
best when there is awareness of the problem and engagement in
the solution at multiple levels of the health care system. HCMV
infection in normal immunocompetent host is usually mild and
subclinical, so it is likely ignored or misdiagnosed.21–23 It is urgent
to raise the public and health care provider’s knowledge of HCMV
infection and its impact on the population. Along with education
of the general population, a priority should be placed on
development of efﬁciently inactivating the virus in maternal
milk without impairment of its immunological and nutritional
constituents, such as pasteurization, freeze-and-thaw and so
forth.24,25 Administration of antivirals to mothers in late
pregnancy may also be effective in preventing perinatal trans-
mission.21 HCMV perinatal prevention programs should ideally
also include a maternal screening program and follow-up of
babies born to infected mothers to monitor infections.21,25 So
there should be a deep commitment to prevention and control of
HCMV infection in central China.
In conclusion, the lower level of HBsAg prevalence among
children can be attributed primarily to the impact of hepatitis B
vaccination and HBIG. Breastfeeding is not a reason for maternal-
to-infant transmission of HBV after the recommended prophylaxis
is implemented. However, viral DNA positive breast milk is a main
source for vertical transmission of HCMV to infants who are not
protected by a standard immunoprophylaxis protocol, but there
are still some measures to be taken to prevent and control HCMV
infection.
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